Search - tctmd.com

Displaying 1 - 20 of 82

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

Podcast TCTMD Talking Points

The CLEAR Outcomes Trial

January 08, 2025

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

Presentation ACC 2024

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Presenter: Steven E. Nissen

April 08, 2024

Podcast TCTMD Talking Points

Lepodisiran Phase I Trial

February 07, 2024

News Daily News

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Yael L. Maxwell

December 13, 2023

Presentation Controversies and Advances 2023

Obesity and Cardiovascular Disease

Presenter: Steven E. Nissen

November 30, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

News Conference News ADA 2023

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

Michael O'Riordan

June 28, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

Advertisement

Year in Review: Top Prevention Stories of 2025

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

The CLEAR Outcomes Trial

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Need a Statin for Primary Prevention? There’s an App for That

Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration

Lepodisiran Phase I Trial

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Obesity and Cardiovascular Disease

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content